---

Disclaimer: This information is provided for educational and informational purposes only and does not constitute medical advice. It is intended for healthcare professionals as a clinical reference. Clinical decisions must always be made based on individual patient circumstances, current clinical guidelines, and the judgment of a qualified healthcare provider. This resource is not a substitute for professional medical judgment, diagnosis, or treatment. Always consult with a healthcare professional for any health concerns or before making any decisions related to patient care.

---

Kawasaki Disease

Overview

• Definition: Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is an acute, self-limiting systemic vasculitis of unknown etiology that primarily affects medium-sized arteries, most notably the coronary arteries. It is characterized by fever and specific clinical criteria.
• Epidemiology:
  • Incidence: KD is the leading cause of acquired heart disease in children in developed countries. Incidence rates vary globally but are highest in Northeast Asian populations, particularly Japan, where the annual incidence can exceed 200 per 100,000 children under 5 years of age. In the United States, the incidence is approximately 19-25 per 100,000 children under 5.
  • Age: The vast majority of cases (approximately 80-85%) occur in children younger than 5 years, with a peak incidence between 6 months and 2 years of age. It is rare in infants younger than 3 months and in children older than 8 years.
  • Sex: There is a male predominance, with a male-to-female ratio of approximately 1.5:1.
  • Seasonality: There is a seasonal predilection, with increased incidence typically observed in winter and spring months.
  • Recurrence: Recurrence is rare (1-3%) but possible.
• Classification:
  • Classic (Complete) Kawasaki Disease: Diagnosed when a child has fever lasting for at least 5 days AND at least four of the five principal clinical criteria (oral changes, peripheral extremity changes, polymorphous rash, bilateral conjunctival injection, cervical lymphadenopathy).
  • Incomplete (Atypical) Kawasaki Disease: Diagnosed when a child has fever for at least 5 days but fewer than four of the principal clinical criteria. This form is more common in infants and older children and often requires supplementary laboratory findings and/or echocardiographic evidence of coronary artery abnormalities for diagnosis. It carries a higher risk of coronary artery aneurysms (CAAs) due to delayed diagnosis.
  • Kawasaki Disease Shock Syndrome (KDSS): A severe manifestation characterized by features of KD along with systolic hypotension (age-specific), signs of poor perfusion, and/or features of shock. It is associated with higher rates of coronary artery abnormalities.
  • Fetal Kawasaki Disease: Extremely rare, reported in neonates with evidence of in-utero coronary artery damage.
  • COVID-19 Associated Multisystem Inflammatory Syndrome in Children (MIS-C) / Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS): Shares some clinical features with KD, particularly the cardiac involvement and inflammatory markers. Differentiating features include older age range, higher rates of shock and myocardial dysfunction, and gastrointestinal symptoms. Management often overlaps with KD but may require additional immunomodulatory therapies.

Pathophysiology

• Mechanism: Kawasaki disease is believed to be an acute systemic vasculitis triggered by an infectious agent or environmental factor in genetically predisposed individuals. The exact etiology remains unknown, but it is thought to involve an aberrant immune response.
  • Immune Activation: An initial trigger (e.g., viral or bacterial infection) leads to activation of the innate immune system (macrophages, neutrophils, dendritic cells), followed by activation of T cells (both CD4+ and CD8+) and B cells.
  • Cytokine Storm: High levels of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6, IL-8, IFN-γ) are observed, contributing to systemic inflammation.
  • Endothelial Damage: Activated immune cells infiltrate the walls of medium-sized arteries, particularly the coronary arteries. This infiltration, combined with the effects of cytokines, causes endothelial cell activation and damage, leading to disruption of the internal elastic lamina and medial smooth muscle cells.
  • Aneurysm Formation: The weakened arterial wall can dilate, leading to the formation of coronary artery aneurysms. This process involves matrix metalloproteinases (MMPs) and their inhibitors (TIMPs). If inflammation persists, it can lead to chronic changes like intimal proliferation, thrombosis, and stenosis.
  • Genetic Predisposition: Polymorphisms in genes related to immune regulation (e.g., ITPKC, ORAI1, CASP3, FCGR2A) and inflammatory pathways are associated with increased susceptibility and risk of CAA.
• Risk Factors:
  • Age: < 5 years, especially 6 months to 2 years. Infants < 6 months have a higher risk of CAA if diagnosed late.
  • Ethnicity: Children of East Asian descent (Japanese, Korean, Chinese) have significantly higher incidence rates.
  • Sex: Male sex.
  • Genetic Predisposition: Family history of KD, specific genetic polymorphisms.
  • Environmental/Infectious Triggers: No specific pathogen identified, but seasonal clustering suggests an infectious trigger. Recent studies link air pollution and specific wind patterns to outbreaks.
• Protective Factors: None are definitively established. Early diagnosis and timely initiation of appropriate treatment (intravenous immunoglobulin - IVIG) are crucial to prevent or minimize coronary artery complications, acting as secondary prevention rather than primary protection.

Clinical Presentation

Signs and Symptoms

The diagnosis of classic KD requires fever for at least 5 days and at least four of the five principal clinical criteria.

• Cardinal Features (CRASH & Burn mnemonic for the 5 criteria + Fever):

  1. Conjunctivitis: Bilateral, non-exudative (no pus), limbal sparing conjunctival injection (redness around the iris is more prominent).
  2. Rash: Polymorphous, non-vesicular, often diffuse maculopapular, scarlatiniform, or erythema multiforme-like. Can involve the perineal area with desquamation.
  3. Adenopathy: Cervical lymphadenopathy, usually unilateral, non-suppurative, firm, and painful, with a diameter >1.5 cm. This is the least consistently observed criterion.
  4. Strawberry Tongue and Oral Cavity Changes: Red, cracked lips; diffuse erythema of the oropharynx; "strawberry tongue" (prominent papillae with a white coating or bright red appearance).
  5. Hands and Feet Changes: Erythema and swelling of the hands and feet (indurated edema of the dorsum). In the subacute phase (2-3 weeks after fever onset), characteristic periungual desquamation (peeling of skin around the nails) occurs. - Burn: Persistent fever, typically high-spiking (often >39°C or 102.2°F), unresponsive to antibiotics and antipyretics, lasting ≥5 days. This is the most consistent and defining feature.

• Early Signs (Acute Phase - Days 0-10 of fever):

  • High-grade, unremitting fever.
  • Irritability.
  • Bilateral conjunctival injection.
  • Erythema and swelling of extremities.
  • Rash.
  • Oral changes.
  • Cervical lymphadenopathy.
  • Diarrhea, vomiting, abdominal pain (less common but can be present).
  • Arthritis/arthralgia (often transient, affecting large weight-bearing joints).
  • Myocarditis, pericarditis (may be asymptomatic, subtle, or manifest as tachycardia out of proportion to fever, gallop rhythm, or signs of heart failure).

• Advanced Signs (Subacute Phase - Weeks 2-4 after fever onset, as fever resolves):

  • Periungual desquamation of fingers and toes.
  • Persistent irritability.
  • Arthritis.
  • Development of coronary artery aneurysms (CAAs) or ectasia.
  • Thrombocytosis (platelet count typically peaks in this phase).
  • Hydrops of the gallbladder (seen on ultrasound, usually resolves spontaneously).
  • Anterior uveitis (often asymptomatic).

• Atypical Presentations (Incomplete KD):

  • Infants (< 6 months): Often present with fewer classic criteria, prolonged fever, extreme irritability, and a higher risk of delayed diagnosis and CAAs. May present with hydrops of the gallbladder, extreme irritability, or aseptic meningitis.
  • Older children (> 5 years): May present with fever and arthralgia/arthritis without other typical features.
  • Masked presentations: Fever may be attributed to other common childhood infections, delaying diagnosis.
  • KDSS: Features of shock, diffuse gastrointestinal symptoms, severe myocardial dysfunction.

Physical Examination

• Inspection:
  • Fever: Document temperature, often high-grade.
  • Conjunctivae: Bilateral injection, typically sparing the limbus. No purulent discharge.
  • Oral Cavity: Red, cracked lips (cheilosis), prominent papillae of the tongue ("strawberry tongue"), diffuse erythema of the pharynx.
  • Rash: Polymorphous, non-vesicular, can be maculopapular, erythematous, or targetoid; often spares the palms and soles initially but can be diffuse. Perineal erythema with subsequent desquamation is characteristic.
  • Extremities: Erythema and firm edema of the palms and soles in the acute phase. Later, periungual desquamation of fingers and toes (typically 2-3 weeks after fever onset).
  • Lymph Nodes: Unilateral, non-tender, firm cervical lymphadenopathy (>1.5 cm diameter).
  • Cardiac: Tachycardia out of proportion to fever, gallop rhythm (S3 or S4), muffled heart sounds, signs of heart failure (e.g., hepatomegaly, rales, peripheral edema in severe cases).
  • Overall: Irritability, decreased activity, signs of systemic inflammation.
• Palpation:
  • Extremities: Evaluate for indurated edema (puffy, firm swelling) of hands and feet.
  • Abdomen: Hepatomegaly may be present (due to heart failure or systemic inflammation). Splenomegaly is less common.
  • Lymph Nodes: Confirm size, tenderness, and mobility of cervical lymph nodes.
• Special Tests: There are no specific "special tests" in the physical exam for KD. The physical examination involves a thorough assessment for the classic diagnostic criteria.

Diagnostic Approach

The diagnosis of KD is clinical, based on the presence of prolonged fever and specific clinical criteria, supported by laboratory and imaging findings.

History Taking

• Key Questions:
  • Fever duration and pattern: When did the fever start? How high? Is it persistent? Does it respond to antipyretics?
  • CRASH symptoms: Specifically inquire about the presence and timing of:
    • Bilateral conjunctival redness (without discharge).
    • Any rash (description, location, progression).
    • Swollen neck glands (size, tenderness, location).
    • Red, cracked lips; red tongue; red throat.
    • Swollen, red hands or feet; peeling skin (when did peeling start?).
  • Irritability: Has the child been unusually irritable?
  • Preceding illness: Any recent viral or bacterial infections? (Note: KD is not directly caused by a specific infection, but a preceding illness can sometimes be a trigger or confound the diagnosis).
  • Cardiac symptoms: Chest pain, shortness of breath, unusual fatigue, abdominal pain, vomiting, diarrhea (may indicate cardiac involvement or KDSS).
  • Exposure history: Recent travel, contact with sick individuals.
  • Family history: Any family history of KD or early-onset heart disease?
  • Medications: What medications have been given (e.g., antibiotics, antipyretics) and their effectiveness?
• Red Flags:
  • Fever >5 days without an apparent source, especially in an infant or young child, and failing to respond to typical antibiotic courses.
  • Any constellation of KD criteria, even if incomplete.
  • Signs of shock or myocardial dysfunction: Hypotension, poor perfusion, extreme tachycardia, lethargy.
  • Severe abdominal pain or vomiting: May indicate KDSS or hydrops of the gallbladder.
  • Prolonged fever with elevated inflammatory markers and an echocardiogram showing coronary artery abnormalities (even in the absence of full clinical criteria).

Laboratory Tests

Laboratory findings in KD are non-specific but reflect systemic inflammation and help support the diagnosis, rule out other conditions, and monitor for complications. - First-Line: - Complete Blood Count (CBC) with differential: - Leukocytosis: Elevated white blood cell count, often with neutrophilia and immature forms, in the acute phase. - Anemia: Mild normocytic, normochromic anemia may be present. - Thrombocytosis: Platelet count usually normal or low in the first week, then significantly elevated (often >450,000/µL, sometimes >1,000,000/µL) in the subacute phase (2-3 weeks after fever onset). - Inflammatory Markers: - Erythrocyte Sedimentation Rate (ESR): Markedly elevated (often >40-60 mm/hr), typically peaks later than CRP. - C-Reactive Protein (CRP): Markedly elevated (often >3 mg/dL or >30 mg/L), peaks within 48-72 hours of fever onset. - Liver Function Tests (LFTs): - Elevated Transaminases (ALT, AST): Common, indicating liver inflammation. - Hypoalbuminemia: Low serum albumin (<3.0 g/dL) is common and is associated with increased risk of IVIG resistance and CAAs. - Urine Analysis (UA): Sterile pyuria (white blood cells in urine without bacterial infection) is common. - Electrolytes and Renal Function (BUN, Creatinine): Generally normal, but important to assess in KDSS. - Pro-Brain Natriuretic Peptide (BNP) or N-terminal pro-BNP (NT-proBNP): May be elevated in patients with myocardial dysfunction or heart failure. - Confirmatory: There is no single confirmatory laboratory test for KD. Diagnosis remains clinical. However, the combination of clinical criteria with consistent lab findings is highly suggestive. - Monitoring: - Repeat CRP/ESR: To monitor response to therapy and resolution of inflammation. Persistent elevation suggests IVIG resistance or ongoing inflammation. - Repeat CBC: To track platelet count for thrombocytosis, which has implications for antiplatelet therapy. - Cardiac Biomarkers (Troponin I/T): If there is concern for myocardial injury.

Imaging

• Recommended:
  • Echocardiogram: Essential for diagnosis and monitoring.
    • Baseline Echocardiogram: Performed promptly upon diagnosis (ideally before IVIG) to assess for coronary artery involvement (dilatation, ectasia, aneurysms), evaluate left ventricular function, presence of pericardial effusion, and mitral regurgitation. Repeat echocardiograms are crucial at 1-2 weeks and 4-6 weeks after initial presentation, or as clinically indicated.
    • Coronary Artery Measurement: Diameter should be measured and indexed to body surface area (BSA) using Z-scores.
      • Ectasia: Z-score ≥2 to <2.5
      • Aneurysm: Z-score ≥2.5 (or absolute internal lumen diameter ≥3 mm for children <5 years, or ≥4 mm for children ≥5 years)
      • Giant Aneurysm: Absolute internal lumen diameter ≥8 mm
• Advanced:
  • Cardiac Magnetic Resonance Imaging (CMRI) / Computed Tomography Angiography (CCTA):
    • Indications: Used for detailed assessment of coronary arteries in children with giant aneurysms, calcified aneurysms, or when echocardiography is suboptimal. CMRI can evaluate myocardial perfusion and fibrosis. CCTA is excellent for lumen visualization but involves radiation.
  • Coronary Angiography: Rarely used for diagnosis, primarily reserved for interventional procedures in patients with severe coronary stenosis or occlusions, or for diagnostic evaluation when non-invasive imaging is inconclusive in older children.
  • Abdominal Ultrasound: May reveal hydrops of the gallbladder (non-specific, but supports diagnosis in atypical cases), hepatomegaly.

Management

The cornerstone of KD management is early initiation of intravenous immunoglobulin (IVIG) and aspirin to reduce inflammation and prevent coronary artery complications.

Acute Management (During the febrile phase, typically within 10 days of fever onset)

• Immediate:
  • Hospital Admission: All patients with suspected or confirmed KD require hospitalization for IVIG administration, close monitoring, and echocardiography.
  • IVIG Administration: Single dose of 2 g/kg administered intravenously over 10-12 hours.
    • Reason: IVIG is a pooled human antibody preparation thought to modulate the immune response, reducing systemic inflammation and the risk of coronary artery aneurysms by up to 80%. It is most effective when given within 10 days of fever onset.
  • Aspirin Administration:
    • High-dose aspirin: 30-50 mg/kg/day or 80-100 mg/kg/day (divided into 3-4 doses).
    • Reason: Aspirin acts as an anti-inflammatory agent during the acute febrile phase.
• Stabilization:
  • Fluid management: Maintain hydration, especially during fever.
  • Antipyretics: Acetaminophen can be used concurrently with aspirin for fever control, but aspirin itself has antipyretic properties.
  • Pain management: For irritability or joint pain.
  • Cardiac monitoring: Continuous cardiac monitoring in patients with signs of myocarditis or KDSS.
• Emergency:
  • Kawasaki Disease Shock Syndrome (KDSS):
    • Fluid resuscitation: Isotonic crystalloids (e.g., normal saline 20 mL/kg boluses).
    • Vasopressors: If hypotension persists despite fluid resuscitation (e.g., norepinephrine, dopamine).
    • Inotropic support: If myocardial dysfunction is significant (e.g., dobutamine, milrinone).
    • Consider early adjunctive therapies: Corticosteroids may be considered upfront in KDSS due to high risk of IVIG resistance and CAAs.
  • Myocardial Infarction: Extremely rare but possible in acute phase with severe CAAs and thrombosis. Managed as per pediatric MI protocols, including thrombolysis or percutaneous coronary intervention in specialized centers.

Chronic Management (After the acute febrile phase, once fever resolves)

• Pharmacological:
  • Aspirin (Low-dose):
    • Dose: 3-5 mg/kg/day, once daily.
    • Duration:
      • No CAAs: Continue until inflammatory markers normalize and follow-up echocardiogram at 4-6 weeks is normal. Typically 6-8 weeks total.
      • Transient Coronary Ectasia (Z-score <2.5 but >2.0): Continue low-dose aspirin for 6-8 weeks until resolution.
      • Small/Medium CAAs (Z-score ≥2.5 to <10, or absolute diameter <8 mm): Continue low-dose aspirin indefinitely or until documented regression (months to years).
      • Large/Giant CAAs (Z-score ≥10, or absolute diameter ≥8 mm): Requires long-term dual antiplatelet therapy (low-dose aspirin + clopidogrel) or anticoagulation (warfarin or low molecular weight heparin, with or without aspirin) due to high risk of thrombosis.
    • Reason: Low-dose aspirin acts as an antiplatelet agent, preventing thrombus formation within the inflamed or aneurysmal coronary arteries.
  • Anticoagulation/Antiplatelet for CAAs:
    • Clopidogrel: 0.2 mg/kg/day orally for severe CAAs, in combination with aspirin.
    • Warfarin: Initiated for giant CAAs or significant coronary stenosis/occlusion, with a target INR of 2.0-2.5. Requires careful monitoring.
    • Low Molecular Weight Heparin (LMWH): Alternative to warfarin, especially in young children where INR monitoring can be challenging.
• Non-pharmacological:
  • Activity Restriction: Children with CAAs, especially giant aneurysms, may require activity restrictions to minimize cardiac stress, under the guidance of a pediatric cardiologist.
  • Vaccinations: Defer live virus vaccines (MMR, Varicella) for 11 months after IVIG administration due to interference from passively acquired antibodies. Inactivated vaccines can be given as scheduled.
  • Influenza Vaccination: Recommended annually for children on long-term aspirin therapy due to the theoretical risk of Reye's syndrome.
• Monitoring:
  • Long-term Echocardiography Follow-up: Schedule depends on initial coronary artery involvement:
    • No CAAs: At 1-2 weeks, 4-6 weeks after diagnosis. If normal, no further routine echoes needed unless new symptoms arise.
    • Transient ectasia: Until resolution.
    • Persistent CAAs: Annual or semi-annual echocardiograms, and potentially stress testing or CMRI/CCTA in older children.
  • Clinical Follow-up: Regular follow-up with a pediatric cardiologist is essential, especially for patients with CAAs, to monitor for long-term complications like stenosis, MI, or sudden cardiac death.
  • Laboratory Monitoring: Periodic CBC (for platelet count) and inflammatory markers if clinically indicated.

Treatment Algorithms

• First-Line (Acute KD):

  1. Diagnosis: Clinical (fever ≥5 days + ≥4/5 classic criteria OR incomplete KD with supporting labs/echo).
  2. Treatment Initiation: Promptly (ideally within 10 days of fever onset) with:
     • IVIG: 2 g/kg IV over 10-12 hours.
     • Aspirin: High-dose (30-50 mg/kg/day or 80-100 mg/kg/day) in 3-4 divided doses.
  3. Monitoring: Clinical improvement (fever resolution), CRP, ESR, baseline and follow-up echocardiograms.
  4. Fever Resolution: After fever-free for 24-48 hours, reduce aspirin to low-dose (3-5 mg/kg/day once daily).

• Second-Line (IVIG-Resistant KD): Approximately 10-20% of patients are IVIG resistant (persistent or recrudescent fever >36 hours after completion of initial IVIG infusion).

  1. Repeat IVIG: A second dose of IVIG (2 g/kg) may be considered, particularly if the initial dose was given late or if there is no immediate access to other therapies.
  2. Corticosteroids:
     • Methylprednisolone pulse therapy: 30 mg/kg/day IV for 1-3 days, followed by oral prednisone taper.
     • Reason: Potent anti-inflammatory and immunomodulatory effects. Evidence supports its use as adjunctive therapy in high-risk patients or for IVIG resistance.
  3. Infliximab:
     • Dose: 5 mg/kg IV as a single dose.
     • Reason: A TNF-α inhibitor, effective in modulating inflammation in some IVIG-resistant cases.
  4. Anakinra:
     • Dose: 1-2 mg/kg/dose subcutaneously, once or twice daily.
     • Reason: An IL-1 receptor antagonist, used in severe or refractory cases, particularly KDSS or those with features resembling MAS.

• Refractory Cases:

  • For patients failing multiple lines of therapy, consultation with a tertiary center experienced in managing complex KD is essential.
  • Other immunomodulatory agents (e.g., cyclophosphamide, etanercept) are rarely used and typically reserved for extreme, life-threatening cases under specialist guidance.
  • Plasmapheresis: Rarely considered for severe, refractory cases.

Complications

The most serious complications of KD involve the cardiovascular system. - Common: - Coronary Artery Aneurysms (CAAs): Occur in 15-25% of untreated patients and 2-5% of IVIG-treated patients. These are the most significant long-term complication. - Myocarditis: Inflammation of the heart muscle, leading to decreased contractility, often transient. - Pericardial Effusion: Fluid around the heart. - Mitral Regurgitation: Due to myocardial dysfunction or papillary muscle involvement. - Arrhythmias: Tachycardia, less commonly other rhythm disturbances. - Serious: - Coronary Artery Thrombosis: Formation of blood clots within CAAs, leading to coronary artery occlusion. This is the leading cause of myocardial infarction (MI) and sudden death in KD patients. - Myocardial Infarction (MI): Occurs due to coronary artery thrombosis or severe stenosis, even years after the acute illness. - Rupture of Coronary Artery Aneurysm: Extremely rare but catastrophic. - Sudden Cardiac Death: Can occur years later due to MI or rupture, particularly in patients with giant CAAs. - Heart Failure: Due to severe myocarditis or extensive coronary artery disease. - Kawasaki Disease Shock Syndrome (KDSS): Severe hypotension and signs of shock, associated with higher CAA rates. - Long-term: - Coronary Artery Stenosis/Occlusion: Aneurysms can regress, but often leave behind intimal thickening and stenosis, leading to chronic coronary artery disease. This can manifest years or decades later. - Chronic Angina and Ischemia: Due to stenotic lesions. - Increased Risk of Atherosclerosis: Debated, but some data suggest an increased risk of premature atherosclerosis in adulthood, even in those without documented CAAs. - Psychological impact: Chronic illness and frequent medical visits can impact quality of life for children and families.

Prognosis

• Factors Affecting Outcome:
  • Timeliness of treatment: IVIG administered within 10 days of fever onset significantly reduces CAA risk.
  • Response to IVIG: IVIG resistance is associated with a higher risk of CAAs.
  • Severity of inflammation: Higher and prolonged inflammatory markers (CRP, ESR) and lower albumin levels are risk factors for CAAs and IVIG resistance.
  • Age: Infants <6 months and children >8 years have a higher risk of incomplete KD and CAAs, often due to delayed diagnosis.
  • Type and size of CAAs: Giant aneurysms carry the highest risk of long-term complications (thrombosis, stenosis, MI).
• Survival: Overall survival rates are excellent with timely diagnosis and treatment. Mortality is <0.1% in developed countries, primarily due to cardiac complications.
• Quality of Life:
  • Most children without CAAs have an excellent long-term prognosis and a normal quality of life.
  • Children with small-to-medium CAAs may have good quality of life but require long-term follow-up and antiplatelet therapy.
  • Children with giant CAAs or significant coronary stenosis face a higher risk of recurrent cardiac events (MI, sudden death) and may experience limitations in physical activity, requiring lifelong specialized cardiac care and potentially surgical interventions (e.g., coronary artery bypass grafting). These patients can have a significantly reduced quality of life.

Prevention

• Primary:
  • Currently, no primary prevention strategies exist as the exact etiology of KD is unknown. Research focuses on identifying triggers and genetic predispositions.
• Secondary:
  • Early Diagnosis and Treatment: This is the most crucial "preventive" measure. Prompt recognition of KD, especially atypical or incomplete forms, and early initiation of IVIG and aspirin within 10 days of fever onset, is the cornerstone to prevent or minimize coronary artery complications.
  • Education: Increasing awareness among healthcare providers and parents about KD symptoms can facilitate earlier presentation and diagnosis.
• Tertiary:
  • Prevention of Complications in Patients with CAAs:
    • Long-term antiplatelet/anticoagulation therapy: To prevent thrombosis within aneurysms.
    • Regular cardiac follow-up: Echocardiography, and sometimes CMRI/CCTA, stress testing to monitor for progression of coronary artery disease.
    • Aggressive management of cardiovascular risk factors: In older patients with a history of KD and CAAs (e.g., hypertension, dyslipidemia, obesity, smoking cessation).
    • Lifestyle modifications: Dietary recommendations, physical activity guidance tailored to the degree of coronary involvement.

Special Populations

• Pediatric: Kawasaki disease is primarily a pediatric disease, so all preceding information directly applies.
  • Infants < 6 months: More prone to incomplete KD and delayed diagnosis, leading to a higher risk of CAAs. Requires a lower threshold for diagnosis and aggressive workup if KD is suspected.
• Geriatric: Extremely rare. KD is almost exclusively a disease of early childhood. If an older adult presents with vasculitis resembling KD, other diagnoses (e.g., adult-onset Still's disease, ANCA-associated vasculitis) should be strongly considered.
• Pregnancy: Extremely rare. No specific guidelines exist due to rarity. Management would likely be tailored to the individual's cardiac status (if pre-existing CAAs) and the specific stage of pregnancy, consulting with maternal-fetal medicine and cardiology.
• Comorbidities:
  • Immunocompromised Patients: Diagnosis can be challenging as fever and rash may be attributed to underlying conditions or infections. IVIG may be less effective in some immunocompromised states.
  • Patients with pre-existing heart disease: Requires careful cardiac assessment and monitoring.
  • COVID-19 Associated Multisystem Inflammatory Syndrome in Children (MIS-C): A distinct but phenotypically similar condition. Shares features with KD (fever, rash, conjunctivitis, cardiac involvement, elevated inflammatory markers). Key differences often include older age, prominent GI symptoms, shock, and severe myocardial dysfunction. Management involves similar immunomodulatory therapies (IVIG, steroids), but may require additional agents like anti-IL-1 or anti-IL-6 therapy and closer cardiac monitoring.

Clinical Pearls

• Diagnostic:
  • Fever is paramount: KD always presents with fever. Without fever, it's not KD.
  • "Look for CRASH, but think about the heart.": The external signs are important for diagnosis, but the internal cardiac complications are the most life-threatening aspect.
  • Incomplete KD is a trap: Be highly suspicious of KD in infants with prolonged unexplained fever and elevated inflammatory markers, even with fewer than 4 classic criteria. Don't wait for all criteria to appear, especially if initial echocardiogram shows coronary changes.
  • Delayed diagnosis in infants: Infants <6 months have a higher risk of developing CAAs due to delayed diagnosis.
  • Sterile pyuria: Common finding, can help differentiate from bacterial UTIs.
  • IVIG is time-sensitive: Aim to give IVIG within 7-10 days of fever onset to maximize benefit.
• Treatment:
  • IVIG + Aspirin is standard: Adhere to the recommended dosages and timing.
  • IVIG resistance: Anticipate and have a plan for IVIG-resistant cases. Persistence of fever >36 hours post-IVIG is the key indicator. High CRP, low albumin, and younger age are risk factors for resistance.
  • Aspirin's dual role: High-dose for anti-inflammatory, low-dose for antiplatelet. Understand when to switch.
  • Live vaccine delay: Remember to counsel parents about delaying live vaccines for 11 months post-IVIG.
• Pitfalls:
  • Misdiagnosing as viral illness: The early symptoms of KD can mimic common viral infections. Persistence of fever and the constellation of signs should raise suspicion.
  • Missing incomplete KD: The most common reason for delayed diagnosis and increased CAA risk, especially in infants.
  • Inadequate cardiac follow-up: Patients with CAAs require lifelong follow-up with a cardiologist. Loss to follow-up can have severe consequences.
  • Stopping aspirin prematurely: Especially in patients with persistent CAAs, this increases the risk of thrombosis.
  • Overlooking KDSS: Shock symptoms may mask typical KD features, leading to delayed diagnosis and treatment of severe disease.

Recent Updates

• Guidelines: The American Heart Association (AHA) periodically updates its scientific statements and guidelines for the diagnosis, treatment, and long-term management of Kawasaki disease. The most recent comprehensive update was in 2017. Specific guidance on MIS-C/PIMS-TS has also emerged from various professional bodies (e.g., CDC, WHO, various pediatric societies) in the context of the COVID-19 pandemic.
• Evidence:
  • Role of Corticosteroids: Growing evidence supports early adjunctive use of corticosteroids, particularly in high-risk patients (e.g., those with a higher predicted risk of IVIG resistance based on scoring systems like the Egami or Kobayashi scores) and in IVIG-resistant cases.
  • Biological Agents: Further studies are exploring the efficacy and safety of biological agents (e.g., infliximab, anakinra, tocilizumab) for refractory KD and KDSS, with promising results in some severe cases.
  • Long-term Outcomes: Ongoing longitudinal studies continue to refine our understanding of long-term cardiovascular risks, including the potential for accelerated atherosclerosis and the need for stringent follow-up into adulthood.
  • MIS-C/PIMS-TS Differentiation: Research continues to elucidate the specific immunological and clinical features that differentiate MIS-C from classic KD, although there is significant overlap.
• Controversies:
  • Optimal management of IVIG-resistant KD: While corticosteroids are increasingly accepted, the optimal sequence and choice of second-line agents (repeat IVIG, infliximab, anakinra) remain areas of active research and debate.
  • Long-term antiplatelet/anticoagulation strategy for regressed aneurysms: The optimal duration of antiplatelet or anticoagulation therapy for patients whose CAAs have regressed or normalized is not fully established.
  • Risk of premature atherosclerosis: While patients with persistent CAAs are at clear risk, the potential for increased cardiovascular risk in adulthood for KD patients without documented CAAs remains an area of ongoing investigation.
  • Genetic testing for susceptibility and prognosis: While genetic markers have been identified, their routine clinical utility for risk stratification or treatment guidance is not yet established.

Key References

• Guidelines:
  • McCrindle, B. W., et al. (2017). Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation, 135(17), e92-e144. (Primary definitive guideline for North America)
  • Japanese Circulation Society Guidelines for Diagnosis and Management of Kawasaki Disease (JCS 2020). Circulation Journal, 86(2), 526-595. (Influential due to high KD incidence in Japan)
• Studies:
  • Newburger, J. W., et al. (1986). A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine, 315(6), 341-347. (Landmark study establishing IVIG efficacy)
  • Kobayashi, T., et al. (2006). Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation, 113(22), 2606-2612. (Developed a scoring system for IVIG resistance)
  • Terai, M., et al. (2010). A randomized trial of intravenous immunoglobulin plus prednisolone for Kawasaki disease with coronary artery abnormality on initial echocardiography. Journal of Pediatrics, 156(5), 844-848. (Evidence for early steroid use)
• Reviews:
  • Ozen, S., et al. (2017). Diagnosis and management of Kawasaki disease in Europe: a European consensus statement. Annals of the Rheumatic Diseases, 76(12), 1957-1967.
  • Eleftheriou, D., & Levin, M. (2015). Kawasaki disease: an overview. Rheumatology, 54(11), 1949-1959.
  • Raphael, J. L., et al. (2018). Kawasaki disease: diagnosis and management. Journal of the American Academy of Physician Assistants, 31(10), 17-21.

---